AbbVie’s Skyrizi was responsible for the highest TV advertising outlay in pharma in most months of 2024, but 2025 is starting ...
Duato discusses the split of the business, dealing with the scrutiny brought about by lawsuits, and 2025 priorities.
The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult ...
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
Q4 2024 Earnings Call Transcript January 22, 2025 Johnson & Johnson beats earnings expectations. Reported EPS is $2.04, ...
Tech entrepreneur and longevity advocate Bryan Johnson has discontinued his use of rapamycin, a controversial anti-ageing ...
Hosted on MSN12d
Johnson & Johnson ketamine-derived nasal spray gets FDA approval for depression, but JNJ stock dips on earningsOn Tuesday, the Food and Drug Administration (FDA) approved Johnson & Johnson’s nasal spray, Spravato (esketamine), to treat ...
neuroscience leader with the drug’s manufacturer, Johnson & Johnson, said in a news release. “For too long, health care providers have had few options to offer patients much-needed symptom ...
13d
Analysts discuss Johnson & Johnson's outlook, highlighting MedTech challenges, litigation risks, pipeline opportunities, and mixed performance across segments.
HealthDay on MSN13d
FDA Approves Spravato Nasal Spray for Treatment-Resistant DepressionWEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an ...
We recently published a list of 12 Safe Stocks to Buy for the Long Term in 2025. In this article, we are going to take a look ...
A one-time nasal spray has been approved by the Food and Drug Administration as a standalone treatment for depression.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback